Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.44 |
| ▸ | FEN1 | P39748 | 4/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.43 |
| ▸ | CDK9 | P50750 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308545 | 0.83 | GPR119 (0.44) | ALOX5APFEN1CCNT1CDK9KDM4E | |
| SCHEMBL2596096 | 0.81 | POLB (0.47) | ALOX5APFEN1KDM4EGPR119 | |
| SCHEMBL31654894 | 0.81 | CCNT1 (0.45) | CCNT1CDK9PDE4BGPBAR1 | |
| SCHEMBL25888787 | 0.81 | CCNT1 (0.45) | CCNT1CDK9PDE4BGPBAR1 | |
| SCHEMBL31655123 | 0.78 | KDM4E (0.41) | ALOX5APFEN1CCNT1CDK9KDM4E | |
| SCHEMBL25888628 | 0.78 | KDM4E (0.41) | ALOX5APFEN1CCNT1CDK9KDM4E | |
| SCHEMBL25888712 | 0.77 | PDE10A (0.49) | ALOX5APFEN1KDM4EGPR119 | |
| SCHEMBL31655333 | 0.77 | PDE10A (0.49) | ALOX5APFEN1KDM4EGPR119 | |
| SCHEMBL30527491 | 0.77 | GPR119 (0.43) | ALOX5APFEN1KDM4EGPR119PDE4B | |
| SCHEMBL25306675 | 0.77 | GPR119 (0.43) | ALOX5APFEN1KDM4EGPR119PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | ALOX5AP 2453/4885FEN1 4852/4885CCNT1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.